Invitae Corp NVTA
We take great care to ensure that the data presented and summarized in this overview for Invitae Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVTA
View all-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA1.28MShares$02.19% of portfolio
-
Alphabet Inc. Mountain View, CA236KShares$00.0% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ158KShares$00.0% of portfolio
-
Eaton Vance Management Boston, MA100KShares$00.0% of portfolio
-
Rayliant Investment Research Santa Monica, CA50.4KShares$00.09% of portfolio
-
American Portfolios Advisors Holbrook, NY47.8KShares$00.0% of portfolio
-
Silverhawk Asset Management, LLC21.6KShares$00.02% of portfolio
-
Newman & Schimel, LLC14.5KShares$00.01% of portfolio
-
Cambridge Trust CO Boston, MA5.41KShares$00.0% of portfolio
-
Strategic Asset Management, LLC5KShares$00.02% of portfolio
Latest Institutional Activity in NVTA
Top Purchases
Top Sells
About NVTA
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Insider Transactions at NVTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2023
|
Robert L Nussbaum Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,404
-3.06%
|
$0
$0.65 P/Share
|
|
Dec 20
2023
|
Thomas Brida |
SELL
Payment of exercise price or tax liability
|
Direct |
17,404
-1.86%
|
$0
$0.65 P/Share
|
|
Nov 13
2023
|
David Sholehvar Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
850,000
+50.0%
|
-
|
|
Oct 18
2023
|
Thomas Brida |
BUY
Grant, award, or other acquisition
|
Direct |
229,500
+19.73%
|
-
|
|
Oct 02
2023
|
Ana J. Schrank Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
850,000
+50.0%
|
-
|
|
Sep 23
2023
|
Robert M. Guigley Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
850,000
+50.0%
|
-
|
|
Jun 13
2023
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
7,079
-1.0%
|
$7,079
$1.38 P/Share
|
|
Jun 13
2023
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,086
-1.23%
|
$7,086
$1.38 P/Share
|
|
May 16
2023
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
45,432
-2.65%
|
$45,432
$1.2 P/Share
|
|
May 16
2023
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
21,559
-5.73%
|
$21,559
$1.2 P/Share
|
|
May 16
2023
|
Yafei Wen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
43,452
-5.84%
|
$43,452
$1.99 P/Share
|
|
May 16
2023
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
26,476
-4.39%
|
$26,476
$1.2 P/Share
|
|
May 16
2023
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
26,476
-3.59%
|
$26,476
$1.2 P/Share
|
|
Apr 27
2023
|
Randal W. Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,422
+30.4%
|
-
|
|
Apr 27
2023
|
Chitra Nayak Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,422
+38.81%
|
-
|
|
Apr 27
2023
|
Eric Aguiar Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,422
+35.98%
|
-
|
|
Apr 27
2023
|
Christine Marie Gorjanc Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,422
+38.81%
|
-
|
|
Apr 27
2023
|
William H Osborne Director |
BUY
Grant, award, or other acquisition
|
Direct |
88,027
+21.67%
|
-
|
|
Apr 27
2023
|
Kimber D Lockhart Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,422
+38.81%
|
-
|
|
Apr 27
2023
|
Geoffrey Crouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,422
+35.09%
|
-
|
Last 12 Months Summary
| Payment of exercise price or tax liability | 34.8K shares |
|---|